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ABSTRACT
Angiotensin II antagonists (AIIAs) were introduced to treat hypertension
about 10 years ago. During this period they were evaluated not only in
terms of efficacy and safety but also in several large studies with clinical
outcomes. They are efficacious in all clinical forms of hypertension and
are effective also in all ethnic groups. Cardiovascular and renal protec-
tion in proteinuric diabetic nephropathy beyond blood pressure reduc-
tion was proved in major clinical studies: Losartan Intervention For End-
point reduction in hypertension study (LIFE), Reduction of Endpoint in
Non-Insulin dependent Diabetes Mellitus with the AII Antagonist Losartan
(RENAAL) and Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT). Their
blood pressure independent protective effect is also mentioned by the
blockade of AT1 receptor. As a class AIIs have a tolerability profile similar
to placebo. (Arq Bras Endocrinol Metab 2006;50/2:327-333)
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RESUMO
Antagonistas da Angiotensina II – Experiência Clínica com o Tratamento
da Hipertensão, Prevenção de Desfechos Cardiovasculares e Proteção
Renal na Nefropatia Diabética e Proteinúria.
Os antagonistas da angiotensina II (AAIIs) foram introduzidos para o
tratamento da hipertensão arterial há cerca de 10 anos. Durante esse
período eles foram avaliados não apenas em termos de eficácia e
segurança, mas também em vários estudos grandes com desfechos
clínicos. Os AAIIs são eficazes em todas as formas clínicas de hiperten-
são e, também, em todos os grupos étnicos. Os principais estudos clíni-
cos em pacientes diabéticos com nefropatia e proteinúia compro-
varam, além da redução da pressão arterial, proteção cardiovascular e
renal: “Losartan Intervention For Endpoint reduction in hypertension
study” (LIFE), “Reduction of Endpoint in Non-Insulin dependent Diabetes
Mellitus with the AII Antagonist Losartan” (RENAAL) e “Irbesartan Type 2
Diabetic Nephropathy Trial” (IDNT). O seu efeito protetor independente
da pressão sanguínea também é mencionado pelo bloqueio do recep-
tor AT1. Os AAIIs, como classe medicamentosa, apresentam um perfil de
tolerabilidade semelhante ao placebo. (Arq Bras Endocrinol Metab
2006;50/2:327-333)
Descritores: Hipertensão; Doença cardiovascular; Diabetes mellitus;
Antagonistas de angiotensina II; Acidente vascular cerebral; Doença
renal terminal; Losartana. 
ANGIOTENSIN II RECEPTOR ANTAGONISTS (AIIAS) were primarily con-ceived for the treatment of hypertension. However the cardiovascular
benefits of AIIAs have been carefully evaluated not only in terms of their
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ability to lower blood pressure in its various clinical
forms but also their ability to prevent cardiac events,
strokes and target organ damage.
This article reviews the large body of data de-
monstrating the efficacy of AIIAs in the treatment of
hypertension, in the regression of left ventricular
hypertrophy and cardiovascular outcomes and in
delaying progression of renal failure in patients with
type II diabetic nephropathy and proteinuria.
AAIIAs as antihypertensive agents
Currently, seven AIIAs are available for the treatment
of hypertension (losartan, candesartan, eprosartan, irbe-
sartan, olmesartan, telmisartan, and valsartan) (1-7).
And each is available as a fixed-dose combination with
a thiazide diuretic. The antihypertensive efficacy of
AIIAs has been demonstrated for in mild-to-moderate
hypertension as well as severe essential hypertension
and isolated systolic hypertension (ISH). AAIIAs are
also described to be effective in different ethnic popu-
lations: Caucasians, Blacks and Asians (8-30).
AIIAs represent an attractive therapeutic option
for the management of systolic hypertension, a condi-
tion difficult to control in clinical practice (31-33).
The ability of AIIAs to impact systolic blood pressure
(SBP) is particularly important since systolic hyper-
tension, particularly ISH, represents a powerful risk
factor for cardiovascular disease, stroke, and end-stage
renal disease (ESRD) and is especially common in
elderly individuals (34,35).
Compared with white persons, individuals who
are black not only suffer from a greater incidence of
hypertension but also tend to have more severe hyper-
tension that is more resistant to effective therapy. Sev-
eral studies have demonstrated the efficacy of AIIAs in
reducing BP in black hypertensive patients (20-22).
However there is evidence from a subanalysis of the
Losartan Intervention for Endpoint reduction study
(LIFE) suggesting that black patients with hyperten-
sion and LVH may not respond as favorably as whites
in terms of CV outcomes benefits (36).
As a class, AIIAs are generally well tolerated
both as monotherapy and in combination with other
antihypertensive drugs. The tolerability profile when
used in combination regimens is an important consi-
deration given that most patients with hypertension
will require administration of multiple agents to ade-
quately control blood pressure. The overall adverse
event profile of AIIAs is generally comparable to place-
bo in randomized clinical trials and superior to that
seen with many other types of antihypertensive agents,
including calcium channel blockers, ACE inhibitors,
diuretics, and beta blockers (37,38). In a global toler-
ability assessment of losartan for the treatment of
hypertension, the overall adverse event for losartan was
similar to that observed for placebo (15.3% vs. 15.5%)
(39). Furthermore, the same excellent tolerability pro-
file was observed in special populations of patients
such as those with heart failure or renal or hepatic
impairment and was uninfluenced by age, race, or gen-
der (39). Similar adverse event profiles have been
reported for all AIIAs.
As observed with ACE inhibitors, however,
AIIAs may be associated with renal dysfunction in
some patients and may give rise to hyperkalemia, espe-
cially in those with renal failure or those receiving
potassium-sparing diuretics (40). Although angioe-
dema occurs much less frequently in patients receiving
AIIA than those receiving ACE inhibitors, it is sug-
gested that AIIAs should be used cautiously in patients
with a history of angioedema, particularly that due to
the use of ACE inhibitors (41).
Clinical trials with AAIIAs in hypertensive
patients
The efficacy of an antihypertensive agent must be
viewed not only in terms of its efficacy in reducing
blood pressure but also in its ability to influence rele-
vant clinical outcomes, like stroke and coronary heart
disease (CHD). Several large outcomes studies have
been conducted with AAIIAs in patients with hyper-
tension: Losartan Intervention For Endpoint reduction
in hypertension (LIFE), Valsartan Antihypertensive
Long-term Use Evaluation (VALUE), and Study on
Cognition and Prognosis in the Elderly (SCOPE) (42-
44). The objective of the LIFE study was to compare
the losartan-based therapy with atenolol-based therapy,
a standard antihypertensive drug with proven CV ben-
efits, on the primary composite endpoint of CV mor-
tality, stroke (fatal and nonfatal), and MI in hyperten-
sive patients (aged 55 to 80 years) with left ventricular
hypertrophy (LVH) (42). Compared with an atenolol-
based regimen, a losartan-based regimen gave rise to a
13.0% relative risk reduction in the primary composite
endpoint of death, MI, or stroke (p= 0.021), a 24.9%
relative risk reduction in fatal or non-fatal stroke (p=
0.001), and a 25% lower incidence of new-onset dia-
betes (p= 0.001). There was no significant difference in
CV mortality or MI between the losartan and atenolol
groups. Blood pressure fell by 30.2/16.6 mmHg and
29.1/16.8 mmHg in the losartan and atenolol groups,
respectively. A lower rate of study drug discontinuation
also occurred in the losartan-based group compared with
the atenolol-based group (13.1% vs. 18.1%, p< 0.001).
AIIAs and Cardiovascular Disease
Ribeiro & Gavras
329Arq Bras Endocrinol Metab vol 50 nº 2 Abril  2006
The LIFE study was sufficiently large to permit
evaluation of the impact of losartan on CV events in
several subsets of patients, including blacks and those
with either diabetes or ISH (45,46). Black patients
with hypertension and LVH did not appear to respond
as favorably as whites in terms of the primary com-
posite endpoint of cardiovascular death, stroke and
MI. In the diabetic hypertensive patients with LVH
studied in the LIFE study (n= 1,195) losartan was
more effective than atenolol in reducing cardiovascular
morbidity and mortality as well as mortality from all
causes. In patients with isolated systolic pressure (n=
1,326) the primary composite endpoint was lower in
the losartan group that in the atenolol group (11.4%
vs. 15.6%, p= 0.06), a difference attributable to stroke
but not MI. Total mortality as well as new-onset dia-
betes were lower in the losartan group.
The results of LIFE are especially important
since they indicate for the first time that losartan seems
to have benefits beyond blood pressure reduction. The
stroke benefits of losartan could potentially have a
great impact on public health, especially since stroke
occurs with greater frequency than MI in patients with
hypertension (47).
The greater cardiovascular benefits of losartan
compared with atenolol observed in LIFE have been
attributed, in part, to decreases in LVH (48). Howe-
ver, other potential mechanisms may also be
involved, including decreased carotid artery hyper-
trophy (49) and fatty streaks (50), decreased risk of
stroke in patients with atrial fibrillation (51),
improvement in endothelial function and structure
(52), inhibition of thromboxane A2-dependent
platelet aggregation (53), and decreased levels of
plasma plasminogen activator inhibitor type-1 anti-
gen (54). A lower incidence of new onset diabetes
mellitus in patients receiving losartan compared with
atenolol may also have contributed to the overall car-
diovascular benefits (see ahead).
SCOPE compared the effects of candesartan
with placebo on CV events, cognitive decline, and de-
mentia in elderly hypertensive patients (43). Patients
were randomly assigned to receive candesartan or
placebo, both in combination with as-needed, open-
label, conventional antihypertensive therapy to attain
blood pressure goals. In the placebo group, appro-
ximately 84% received open-label antihypertensive
therapies that included diuretics, ACE inhibitors, beta-
blockers, or calcium channel blockers. Although can-
desartan produced a 27.8% reduction in non-fatal
stroke compared with usual antihypertensive treat-
ment, no significant differences were apparent
between candesartan and control groups for the pri-
mary endpoint (CV death, non-fatal MI, or non-fatal
stoke), for the secondary endpoint measures of all
stroke, fatal stroke, MI, cardiovascular mortality, or for
the proportion of patients with cognitive
decline/dementia. Unlike the LIFE study, however,
small differences in blood pressure (3.2/1.6 mmHg)
in favor of the candesartan group may have con-
tributed, at least in part, to the stroke benefit seen in
patients receiving a candesartan-based therapy.
VALUE investigated the hypothesis that, in
hypertensive patients at high risk of cardiac events, val-
sartan would be more effective than amlodipine in pre-
venting cardiac morbidity and mortality for an equiva-
lent degree of blood pressure lowering (44,55). The
study revealed no difference in primary composite
endpoint of cardiac morbidity and mortality or in all-
cause mortality outcome between the valsartan and
amlodipine groups. However, more valsartan patients
than amlodipine patients experienced MIs (HR= 1.19,
p= 0.02) and fatal and nonfatal strokes (HR= 1.15, p=
0.08). As observed in SCOPE, dissimilarities in
achieved blood pressure occurred between the two
study groups, a difference that was particularly appar-
ent during the first 6 months of therapy. In fact, at
both the beginning and throughout the trial, patients
receiving amlodipine had better blood pressure con-
trol than those receiving valsartan. For example, more
amlodipine-treated patients than valsartan-treated
patients achieved the combined systolic/diastolic
blood pressure target of < 140/90 mmHg (62% vs.
56%, respectively).
AIIAS and new onset diabetes
Compared with diuretics, beta-blockers, or calcium
channel blockers, a consistently lower incidence of
type 2 diabetes in hypertensive patients has been
observed following treatment not only with AIIAs but
also with ACE inhibitors (56). The underlying mech-
anisms involved in this effect are not fully understood
but may involve: improved blood flow to skeletal mus-
cles, thereby, enhancing insulin and glucose delivery
to the insulin-sensitive tissues; facilitation of insulin
signaling at the cellular level and improved secretion of
insulin from the beta cells. The Nateglinide And Val-
sartan in Impaired Glucose Tolerance Outcomes
Research (NAVIGATOR) trial and ONgoing Telmis-
artan Alone and in combination with Ramipril Global
Endpoint Trial (ONTARGET) are currently ongoing
and will provide further information on diabetes pre-
vention by AIIAs as well as their impact on prevention
of events and on mortality (57,58).
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DIABETIC NEPHROPATHY
Antihypertensive therapy reduces the rate of decline in
renal function and delays end-stage renal disease
(ESRD) in patients with diabetic nephropathy and,
thus, represents a cornerstone of treatment for any
diabetic patient with high blood pressure. AIIAs have
been shown to consistently produce favorable mortal-
ity and morbidity outcomes in endpoint trials in
patients with type 2 diabetes and diabetic nephropathy
(59,60). Results from the RENAAL and IDNT stud-
ies demonstrating that AAIIAs delays progression of
renal deterioration in patients with clinical diabetic
nephropathy and proteinuria will be reviewed. The
favorable results in patients with microalbuminuria are
presented in other paper of this issue.
RENAAL (59) compared the effects of losartan
with placebo (both administered in addition to con-
ventional antihypertensive therapy, including calcium
channel blockers, diuretics, alpha-blockers, beta-
blockers, and centrally acting agents) in patients with
type 2 diabetes and nephropathy, defined as a urinary
albumin/creatinine ratio of at least 300 mg/g and
serum creatinine between 1.3 to 3.0 mg/dL. The pri-
mary endpoint was a composite of the time to first
event of doubling of serum creatinine, ESRD, or
death, with secondary endpoints of cardiovascular
events, progression of renal disease, and changes in
proteinuria. Patients treated with losartan demonstrat-
ed a 16% reduction (p= 0.02) in the composite end-
point, a 25% risk reduction in doubling of serum crea-
tinine (p= 0.006), a 28% reduction in the risk of ESRD
(p= 0.002), and a 20% risk reduction in the composite
endpoint of ESRD and death (p= 0.01), compared
with patients receiving placebo. However, losartan was
not associated with a significant reduction in the death
rate. Losartan-treated patients also experienced a 35%
decrease in proteinuria, as shown by a significant fall in
the urine albumin/creatinine ratio (p< 0.001). Losar-
tan did not impact the composite endpoint of CV
morbidity or mortality but did reveal evidence of car-
dioprotection, as evidenced by a 32% reduction in risk
of first hospitalization for heart failure (p= 0.005).
Both study groups had similar trough systolic and
diastolic blood pressures throughout the study, a find-
ing that indicates that the renoprotective effects of
losartan were attributable to effects beyond blood
pressure control.
Similar renoprotective effects were obtained
with irbesartan in the IDNT study. IDNT (59), which
compared irbesartan with amlodipine on the progres-
sion of nephropathy in patients with type 2 diabetes,
showed that irbesartan was associated with a lower risk
of the primary composite endpoint of doubling of the
base-line serum creatinine concentration, the develop-
ment of ESRD, or death from any cause (20% lower
risk vs. placebo, p= 0.02); 23% lower risk vs. amlodip-
ine, p= 0.006), a lower risk of doubling of serum cre-
atinine concentration (33% lower risk vs. placebo, p=
0.003; 37% lower risk vs. amlodipine, p= 0.001), and
a lower relative risk of ESRD although not statistically
significant (23% vs. either group, p= 0.07). The study
groups were similar with respect to all-cause mortality
and the secondary composite endpoint of cardiovascu-
lar events. The serum creatinine concentration also
increased more slowly in patients receiving irbesartan
(24% more slowly vs. placebo, p= 0.008; 21% more
slowly vs. amlodipine, p= 0.02). As with RENAAL,
the overall benefits favoring AIIA occurred despite the
fact that blood pressure control was generally compa-
rable among the study groups. However, mean arteri-
al pressure was significantly higher by 3.3 mmHg in
placebo group vs. other two treatment groups (p=
0.001 for both comparisons), although this did not
appear to influence the results after statistical analysis
was performed.
Potential mechanisms of renoprotection
beyond blood pressure control
In patients with diabetes, AII is believed to play a cen-
tral role in the progression of renal damage not only
through hemodynamic effects but also nonhemody-
namic effects, including stimulation of growth factors
and cytokines and alterations in extracellular matrix
metabolism (61,62). AII gives rise to glomerular
hypertension and can alter the filtration properties of
the glomerular basement membrane, leading to pro-
teinuria (63,64). AII can also produce glomerular scle-
rosis via stimulation of transforming growth factor-β,
endothelin, and vascular endothelium growth factor
and modulation of extracellular matrix (60,61).
In addition to the favorable impact of AIIAs
on hypertension and renal hemodynamics, AIIAs
may block AII’s growth-promoting, profibrotic,
nonhemodynamic effects, and this too may con-
tribute to the observed renoprotection. For exam-
ple, losartan may produce renoprotective benefits by
lowering the fibrogenic cytokine TGF-β (64),
reducing proteinuria, decreasing renal oxidative
stress (65), preserving glomerular and tubulointer-
stitial structure (66), and reducing the glomerular
membrane pore size (62).
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